CD8A and non-small cell lung carcinoma: Therefore, like in common EGFR-mutant NSCLC patients, combination of CD8+ TILs and PD-L1 level in TME can determine the anti-PD-1/PD-L1 therapy efficacy for NSCLC patients with uncommon EGFR mutations (Chen et al., 2020).